文献速递血栓与止血

罗米司亭用于围手术期血小板减少症的管理

Romiplostim for the management of perioperative thrombocytopenia.
PubMed 文献 · Br J Haematol · 2018-05-16

这项单中心回顾性综述分析了47例接受51次手术的血小板减少症患者围手术期使用罗米司亭的情况。中位血小板计数从用药前的47×10^9/L升至手术时的164×10^9/L(P<0.0001),96%的手术按计划进行。出血和血栓栓塞事件在此类手术人群中处于可接受范围。

要点

  • 罗米司亭使中位血小板计数从47×10^9/L升至164×10^9/L,96%手术按计划进行。
  • 每周3μg/kg共2剂可使79%患者在14天内血小板升至>100×10^9/L。
  • 4例出血事件与血小板减少无关,1例发生深静脉血栓,出血和血栓事件在可接受范围。

核心结论

  • 罗米司亭能有效提升血小板计数,使手术安全且按计划进行,出血和血栓栓塞事件在此类手术人群中处于可接受范围。

研究设计与样本

  • 单中心回顾性综述,纳入47例接受51次手术的围手术期使用罗米司亭的血小板减少症患者。

主要发现

  • 中位(范围)血小板计数从罗米司亭启动时的47×10^9/L(9-120×10^9/L)升至手术时的164×10^9/L(28-603×10^9/L),P<0.0001。
  • 每周3μg/kg共2剂使79%的患者在14天内血小板计数升至>100×10^9/L。
  • 96%的病例手术按计划进行,未延迟或取消。
  • 4例患者发生与血小板减少无关的出血事件,1例患者发生深静脉血栓。
  • 6例患者围手术期需要红细胞输注,3例需要血小板输注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombocytopenic patients requiring invasive surgery have few options to improve their platelet count preoperatively. This is a single-centre, retrospective review of thrombocytopenic patients receiving the thrombopoietin receptor agonist romiplostim perioperatively to allow for surgical interventions. Patient characteristics, romiplostim use, and surgical and safety outcomes (bleeding, thrombosis, transfusions) were collected and analysed. Forty-seven patients underwent 51 surgical procedures (ranging from total hip arthroplasty to open cardiac surgery) with romiplostim support. Thrombocytopenia aetiologies included immune thrombocytopenia, chronic liver disease, haematological malignancy, drug-related thrombocytopenia, and hereditary thrombocytopenia. Median (range) platelet counts improved, from 47 × 109 /l (9-120 × 109 /l) at romiplostim initiation to 164 × 109 /l (28-603 × 109 /l) at the time of surgery (P < 0·0001). A dose of 3 μg/kg per week for 2 doses increased the platelet count to >100 × 109 /l in 79% of patients within 14 days. In 96% of cases, surgery proceeded on schedule without delay or cancellation. Four patients had bleeding events unrelated to thrombocytopenia and 1 patient developed deep venous thrombosis. Six patients required red cell transfusion and 3 patients required platelet transfusion perioperatively. In conclusion, romiplostim was effective in increasing platelet counts to allow surgery to proceed safely and on schedule. Bleeding and thromboembolic events were within acceptable limits for this surgical population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Marshall AL, Goodarzi K, et al. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018. PMID: 29767837. doi:10.1111/bjh.15280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。